- Stocks
- Healthcare
- NASDAQ: IONS

Price (delayed)

$61.27

Market cap

$8.57B

P/E Ratio

120.14

Dividend/share

N/A

EPS

$0.51

Enterprise value

$8.75B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and

IONS's revenue is up by 14% YoY

The gross profit is up by 13% year-on-year

IONS's P/E is 112% above its last 4 quarters average of 56.8

Ionis Pharmaceuticals's EPS has shrunk by 84% YoY and by 45% QoQ

What are the main financial stats of IONS

Market
Valuations
Earnings

Shares outstanding

139.82M

Market cap

$8.57B

Enterprise value

$8.75B

Price to earnings (P/E)

120.14

Price to book (P/B)

6.19

Price to sales (P/S)

9.18

EV/EBIT

57.03

EV/EBITDA

52.15

EV/Sales

9.39

Revenue

$932.66M

EBIT

$153.5M

EBITDA

$167.88M

Free cash flow

$178.11M

Per share
Balance sheet
Liquidity

EPS

$0.51

Free cash flow per share

$1.27

Book value per share

$9.9

Revenue per share

$6.68

TBVPS

$21.96

Total assets

$3.1B

Total liabilities

$1.49B

Debt

$820.66M

Equity

$1.38B

Working capital

$2.29B

Debt to equity

0.59

Current ratio

10.37

Quick ratio

9.68

Net debt/EBITDA

1.12

Margins
Efficiency
Dividend

EBITDA margin

18%

Gross margin

99%

Net margin

7.9%

Operating margin

11.9%

Return on assets

2.3%

Return on equity

5.3%

Return on invested capital

5%

Return on capital employed

5.4%

Return on sales

16.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ionis Pharmaceuticals stock price performed over time

Intraday

-2.03%

1 week

-0.13%

1 month

10.72%

1 year

2.08%

YTD

8.37%

QTD

8.37%

How have Ionis Pharmaceuticals's revenue and profit performed over time

Revenue

$932.66M

Gross profit

$923.01M

Operating income

$111.24M

Net income

$73.4M

Gross margin

99%

Net margin

7.9%

The company's net margin has shrunk by 85% YoY and by 43% QoQ

The net income has dropped by 83% year-on-year and by 44% since the previous quarter

IONS's operating income is down by 26% since the previous quarter and by 4.1% year-on-year

The operating margin has declined by 26% since the previous quarter and by 16% year-on-year

What is Ionis Pharmaceuticals's growth rate over time

What is Ionis Pharmaceuticals stock price valuation

P/E

120.14

P/B

6.19

P/S

9.18

EV/EBIT

57.03

EV/EBITDA

52.15

EV/Sales

9.39

IONS's P/E is 112% above its last 4 quarters average of 56.8

Ionis Pharmaceuticals's EPS has shrunk by 84% YoY and by 45% QoQ

The stock's price to book (P/B) is 64% less than its 5-year quarterly average of 17.4 but 17% more than its last 4 quarters average of 5.3

The company's equity rose by 3.5% YoY

The P/S is 23% less than the 5-year quarterly average of 11.9 but 21% more than the last 4 quarters average of 7.6

IONS's revenue is up by 14% YoY

How efficient is Ionis Pharmaceuticals business performance

IONS's return on equity has dropped by 85% year-on-year and by 44% since the previous quarter

IONS's return on assets has dropped by 85% year-on-year and by 45% since the previous quarter

Ionis Pharmaceuticals's return on sales has decreased by 30% YoY and by 20% QoQ

Ionis Pharmaceuticals's ROIC has decreased by 25% YoY and by 21% from the previous quarter

What is IONS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IONS.

How did Ionis Pharmaceuticals financials performed over time

The total assets is 108% greater than the total liabilities

The company's debt is 41% lower than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.